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Cancer Vaccines: A Ray of Hope 
Abstract 
In lieu of an abstract, here are the article's first two paragraphs: 
Recent cancer statistics review by Surveillance, Epidemiology, and End Results (SEER) Program by 
National Cancer Institute (NCI) shows that cancer is the second most leading cause of death after heart 
diseases. Cancer incidence has grown from 19.2% to 23.3% from 1975 to 2010 (Figure 1)[1]. Lung cancer 
remains to be the most fatal form of cancer followed by colorectal, breast and prostate cancer in the 
country (Table 1)[1]. Regardless of several treatment options, cancer remains to be a unique challenge for 
both patients and the healthcare providers. Several treatment options are available to address this 
disease now. Chemotherapy, surgery, radiation therapy are still the mainline of treatment plan for cancer 
patients. Along with these therapies, immunotherapy is being explored as a combination therapy. 
Immunotherapy allows utilization of patient’s own immune system to combat the disease and⁄or assist in 
avoiding a relapse. 
Cancer research and clinical trials are one of the most challenging ones attributed to the nature of the 
disease state. This editorial is devoted to those, who have dedicated their careers to develop various 
immunotherapeutic approaches leading to the evolution of cancer vaccines, providing a ray of hope to 
cancer patients. These cancer vaccines are targeted to boost the immune response of the host further 
protecting them from the challenges posed by cancerous cells. Unlike vaccines for infectious diseases, a 
cancer vaccine is targeted against host’s own cells. Thus, identification and isolation of such cancer 
antigens is not only difficult but also unique for the patient at times. 
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Corporation) is the only FDA approved therapeutic cancer vaccine. 
Sipuleucel-T is a therapeutic cancer vaccine for metastatic prostate 
cancer in males. Treatment with Sipuleucel-T is individualized; it 
involves isolation of patient’s immune cells using leukapheresis and 
then activation of their antigen presenting cells (APCs) ex vivo with 
prostatic acid phosphatase and granulocyte-macrophage colony-
stimulating factor (PAP-GM-CSF). PAP is the prostate cancer 
antigen, which is overexpressed in prostate cancer patients and 
activation of APCs with PAP in presence of an immunostimulant 
(GM-CSF) triggers an immune response. These activated APCs are 
infused back into the patient leading to an immune response against 
the cancerous cells expressing PAP antigen. These patients receive 
three such treatments in an interval of two weeks each to obtain the 
therapeutic effect. Sipuleucel-T based clinical trials have resulted in 
an increase in survival rate of men suffering from metastatic prostate 
cancer by an average of four months. Various limitations of being 
eligible for the therapy, the cost and effort required to conduct the 
procedure, reduced the number of patients being benefited by this 
therapeutic vaccine. 
Considering the potential of these cancer vaccines, various 
ongoing clinical trials are utilizing different approaches to develop 
cancer vaccines.Some of the antigen sources for these vaccines are:
•	 Viral antigens 
•	 Whole cell lysates of cancer cells/weakened cancer cells
•	 Protein/carbohydrate/glycolipid/ganglioside based cancer 
antigens derived from cancer cells
•	 DNA/RNA fragments responsible for tumor associated 
antigens (TAAs)
Various immunostimulants/adjuvants have been employed to 
enhance the immune response against these antigens, some examples 
As we put forth the inaugural issue of Austin Journal of Cancer 
and Clinical Research, I would like to take this opportunity to welcome 
the readers and encourage fellow peers in academia, industry, 
government and related healthcare professionals to contribute their 
research work and expert reviews to the journal. 
Recent cancer statistics review by Surveillance, Epidemiology, 
and End Results (SEER) Program by National Cancer Institute (NCI) 
shows that cancer is the second most leading cause of death after 
heart diseases. Cancer incidence has grown from 19.2% to 23.3% 
from 1975 to 2010 (Figure 1)[1]. Lung cancer remains to be the most 
fatal form of cancer followed by colorectal, breast and prostate cancer 
in the country (Table 1)[1]. Regardless of several treatment options, 
cancer remains to be a unique challenge for both patients and the 
healthcare providers. Several treatment options are available to 
address this disease now. Chemotherapy, surgery, radiation therapy 
are still the mainline of treatment plan for cancer patients. Along with 
these therapies, immunotherapy is being explored as a combination 
therapy. Immunotherapy allows utilization of patient’s own immune 
system to combat the disease and/or assist in avoiding a relapse.
Cancer research and clinical trials are one of the most challenging 
ones attributed to the nature of the disease state. This editorial is 
devoted to those, who have dedicated their careers to develop various 
immunotherapeutic approaches leading to the evolution of cancer 
vaccines, providing a ray of hope to cancer patients. These cancer 
vaccines are targeted to boost the immune response of the host further 
protecting them from the challenges posed by cancerous cells. Unlike 
vaccines for infectious diseases, a cancer vaccine is targeted against 
host’s own cells. Thus, identification and isolation of such cancer 
antigens is not only difficult but also unique for the patient at times.
Cancer vaccines are classified into two categories: prophylactic 
and therapeutic. Prophylactic cancer vaccines are preventive vaccines, 
currently there are two such vaccines available against cervical cancer. 
Cervical cancer is caused by human papilloma virus (HPV) and 
currently two FDA approved vaccines, Gardasil® and Cervarix®, are 
available for its prevention. On the other hand, therapeutic vaccines 
are administered post cancer diagnosis and are for  treatment 
purposes. Currently, Sipuleucel-T (Provenge® by Dendreon 
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Common Types of Cancer Estimated New Cases 2013
Estimated 
Deaths 2013
All Cancer Sites 1,660,290 580,350
1. Lung and Bronchus Cancer 228,190 159,480
2. Colon and Rectum Cancer 142,820 50,830
3. Breast Cancer 232,340 39,620
4. Prostate Cancer 238,590 29,720
5. Non-Hodgkin Lymphoma 69,740 19,020
6. Bladder Cancer 72,570 15,210
7. Kidney and Renal Pelvis Cancer 65,150 13,680
8. Melanoma of the Skin 76,690 9,480
9. Endometrial Cancer 49,560 8,190
10. Thyroid Cancer 60,220 1,850
Table 1: Estimated number of new cancer cases and deaths in 2013 (SEER stat 
fact sheet).
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include: granulocyte-macrophage colony-stimulating factor (GM-
CSF), Bacillus Calmette-Guérin (BCG), cytosine phosphate-guanine 
(CpG), interleukin-2/ interleukin-12, mono-phosphoryl lipid A 
(MPL), etc[2].
With several promising cancer vaccine based clinical trials in the 
pipeline, we continue to explore the potential of developing another 
line of therapy for cancer patients. With this, I congratulate Austin 
Journal of Cancer and Clinical Research for the inaugural issue and 
encourage the readers to contribute to the scientific community 
through the journal. 
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